Alector uses a genetics‑first platform to identify protein pathways linked to neurodegeneration and develops CNS‑penetrant therapeutics—including monoclonal antibodies, engineered proteins, and gene‑delivery vectors—that clear toxic aggregates or modulate microglial activity. Its programs incorporate biomarker‑guided patient stratification and adaptive trial designs to accelerate development of disease‑modifying treatments for Alzheimer’s disease, frontotemporal dementia, and ALS.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HCFounders
Product
Problem
Neurodegenerative disorders such as Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis progress through accumulation of toxic proteins and loss of neuronal and immune cell function, yet disease‑modifying therapies remain scarce. The underlying molecular pathways are complex, and conventional drug discovery often fails to translate genetic insights into effective treatments.
Solution
Alector applies an integrated genetics‑first platform to pinpoint protein pathways that drive neurodegeneration. By leveraging human genomic data, neuroscience, and immunology, the company designs therapeutic candidates that either clear pathogenic proteins, supplement missing functional proteins, or re‑engineer microglial and neuronal signaling to restore brain homeostasis. Its pipeline spans multiple modality classes—including monoclonal antibodies, engineered proteins, and gene‑delivery vectors—optimized for central nervous system (CNS) penetration. Early‑stage programs incorporate biomarker‑guided patient stratification and adaptive trial designs to accelerate go/no‑go decisions. The overarching goal is to deliver first‑in‑class or best‑in‑class medicines that alter disease trajectory rather than merely address symptoms.
Target Audience
Primary customers are pharmaceutical partners and clinical research organizations developing disease‑modifying therapies for neurodegenerative conditions, as well as the patient populations affected by Alzheimer’s disease, frontotemporal dementia, and ALS.
Features
- Human‑genetics driven target discovery pipeline that prioritizes genes with strong disease association and tractable protein products.
- Multi‑modal therapeutic engineering (e.g., Fc‑engineered antibodies, bispecifics, AAV‑based gene therapies) tailored for efficient blood‑brain barrier crossing.
- Proprietary protein‑clearance mechanisms that harness endogenous proteostasis pathways to eliminate toxic aggregates.
- Immune‑modulatory platforms that reprogram microglial activity to support neuroprotection and synaptic maintenance.
- Integrated biomarker suite (CSF, PET, plasma) enabling patient enrichment and real‑time pharmacodynamic readouts.
- Adaptive clinical development framework that leverages interim data to refine dosing, endpoints, and cohort selection.
- Scalable GMP manufacturing processes aligned with both biologics and viral vector production standards.